A recent retrospective study looking at daratumumab in addition to and without chemotherapy in relapsed or refractory T-ALL further supports that there may be therapeutic effect in targeting CD38 in relapsed or refractory T-ALL [63]. Here, CD38 is linked to acute lymphoblastic leukemia.